Archit Organosys FY26 Net Profit Surges 59% to ₹803.21 Lakh; Newspaper Ad Disclosure Filed
Archit Organosys reported a 59% YoY surge in FY26 net profit to ₹803.21 lakh, with revenue from operations rising to ₹14,095.25 lakh. The Board recommended a final dividend of ₹1 per equity share. On May 18, 2026, the company filed a newspaper advertisement disclosure with BSE under Regulation 30 and Regulation 47 of SEBI LODR, confirming publication of audited financial statements in Western Times on May 17, 2026, and also notified shareholders of a special window for re-lodgement of physical share transfer requests open from February 5, 2026 to February 4, 2027.
*this image is generated using AI for illustrative purposes only.
Archit Organosys has reported its standalone audited financial results for the quarter and year ended March 31, 2026. The Board of Directors, at their meeting held on May 16, 2026, approved the results and recommended a final dividend of ₹1 per equity share (10%) of ₹10 each for the financial year ended March 31, 2026, subject to shareholder approval at the ensuing Annual General Meeting. The statutory auditors, M/s G.K. Choksi & Co., Chartered Accountants, issued an unmodified audit opinion on the standalone audited financial results. Subsequently, on May 18, 2026, the company filed a newspaper advertisement disclosure with BSE Limited under Regulation 30 read with Schedule III Part A Para A and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirming that the audited financial statements were published in Western Times (English Edition) and Western Times (Gujarati Edition) on Sunday, May 17, 2026. The advertisement included a QR code and weblink to access the complete audited financial statements, which are also available on the company's website at www.architorg.com and on the BSE website.
Full Year Financial Performance
Archit Organosys delivered a strong performance for the full year ended March 31, 2026, with net profit rising sharply on the back of higher revenues and improved operating efficiency. The following table summarises the key annual financial metrics:
| Metric: | FY26 (₹ in Lacs) | FY25 (₹ in Lacs) |
|---|---|---|
| Revenue from Operations | 14,095.25 | 12,559.92 |
| Other Income | 288.46 | 309.28 |
| Total Income | 14,383.71 | 12,869.20 |
| Total Expenses | 13,284.46 | 12,115.31 |
| Profit Before Tax | 1,099.25 | 753.89 |
| Net Profit | 803.21 | 505.11 |
| EPS – Basic (₹) | 3.91 | 2.46 |
| EPS – Diluted (₹) | 3.91 | 2.46 |
| Total Comprehensive Income | 805.27 | 505.94 |
Expense Breakdown
Total expenses for FY26 stood at ₹13,284.46 lakh against ₹12,115.31 lakh in FY25. The detailed expense composition for the full year is presented below:
| Expense Head: | FY26 (₹ in Lacs) | FY25 (₹ in Lacs) |
|---|---|---|
| Cost of Materials Consumed | 3,406.75 | 4,011.92 |
| Purchase of Stock in Trade | 6,295.99 | 4,852.73 |
| Changes in Inventories | 138.23 | (106.08) |
| Employee Benefits Expenses | 737.00 | 710.15 |
| Finance Costs | 228.82 | 257.98 |
| Depreciation & Amortisation | 601.44 | 594.23 |
| Power and Fuel | 398.44 | 440.24 |
| Other Expenses | 1,477.79 | 1,354.14 |
| Total Expenses | 13,284.46 | 12,115.31 |
Quarterly Results Summary
For the quarter ended March 31, 2026, Archit Organosys reported a net profit of ₹202.22 lakh on total income of ₹3,602.88 lakh. This compares with a net profit of ₹201.75 lakh on total income of ₹4,424.75 lakh for the quarter ended March 31, 2025. Revenue from operations for the quarter stood at ₹3,649.89 lakh.
| Metric: | Q4 FY26 (₹ in Lacs) | Q3 FY26 (₹ in Lacs) | Q4 FY25 (₹ in Lacs) |
|---|---|---|---|
| Revenue from Operations | 3,649.89 | 3,839.81 | 4,318.33 |
| Total Income | 3,602.88 | 3,930.05 | 4,424.75 |
| Total Expenses | 3,356.15 | 3,579.38 | 4,094.12 |
| Profit Before Tax | 246.73 | 350.67 | 330.63 |
| Net Profit | 202.22 | 243.48 | 201.75 |
| EPS – Basic (₹) | 0.99 | 1.19 | 0.98 |
Balance Sheet Highlights
As at March 31, 2026, total assets stood at ₹12,667.17 lakh compared to ₹12,291.87 lakh as at March 31, 2025. Total equity improved to ₹7,623.27 lakh from ₹6,920.57 lakh, reflecting the accretion of profits during the year. Key balance sheet items are summarised below:
| Particulars: | 31st March 2026 (₹ in Lacs) | 31st March 2025 (₹ in Lacs) |
|---|---|---|
| Non-current Assets | 6,575.19 | 6,142.23 |
| Current Assets | 6,091.98 | 6,149.64 |
| Total Assets | 12,667.17 | 12,291.87 |
| Equity Share Capital | 2,052.07 | 2,052.07 |
| Other Equity | 5,571.20 | 4,868.50 |
| Total Equity | 7,623.27 | 6,920.57 |
| Non-current Liabilities | 722.29 | 801.13 |
| Current Liabilities | 4,321.61 | 4,570.17 |
| Total Liabilities | 5,043.90 | 5,371.30 |
Within current assets, trade receivables stood at ₹2,454.84 lakh (FY25: ₹2,304.79 lakh), while cash and cash equivalents improved significantly to ₹137.41 lakh from ₹6.81 lakh. Non-current borrowings declined to ₹280.68 lakh from ₹448.79 lakh, reflecting debt repayment during the year.
Cash Flow Statement
The company generated net cash from operating activities of ₹268.46 lakh for FY26, compared to ₹1,852.01 lakh in FY25. Net cash from investing activities was ₹439.28 lakh, a reversal from the outflow of ₹2,084.73 lakh in FY25, primarily driven by inter-corporate deposit recoveries and interest received. Cash used in financing activities was ₹577.14 lakh against ₹142.77 lakh in FY25.
| Cash Flow Head: | FY26 (₹ in Lacs) | FY25 (₹ in Lacs) |
|---|---|---|
| Net Cash from Operating Activities | 268.46 | 1,852.01 |
| Net Cash from Investing Activities | 439.28 | (2,084.73) |
| Net Cash used in Financing Activities | (577.14) | (142.77) |
| Net Increase / (Decrease) in Cash | 130.60 | (375.49) |
| Cash at Beginning of Year | 6.81 | 382.30 |
| Cash at End of Year | 137.41 | 6.81 |
Dividend, Regulatory Disclosures and Other Information
The Board has recommended a final dividend of ₹1.00 per equity share (10% of face value of ₹10 each) for FY26, subject to shareholder approval at the ensuing Annual General Meeting. The company operates in a single reportable segment — Chemicals and Organics — in line with Ind AS 108. It has no subsidiary, associate, or joint venture, and hence consolidated financial results are not applicable. The paid-up equity share capital remains unchanged at ₹2,052.07 lakh.
In accordance with SEBI circular No. HO/38/13/1(2) 2026-MIRSD-POD/1/3750/2026 dated 30th January, 2026, a special window for transfer and dematerialisation of physical shares sold or purchased prior to April 01, 2019, has been opened for a period of one year from February 5, 2026 to February 4, 2027. This window is open only for re-lodgement of transfer deeds that were lodged prior to the deadline of April 1, 2019 and were rejected, returned, or not attended to due to deficiency in documents or process. Shares re-lodged for transfer will be issued only in demat mode under a lock-in of one year from the date of registration of transfer, and shall not be transferred, sold, or pledged during the lock-in period. Disputed cases and IEPF transferred shares are not eligible under this window. Shareholders may submit the required documents to the Registrar and Share Transfer Agent, MUFG Intime India Private Limited (formerly Link Intime India Pvt Ltd), C-101, Embassy 247, L B S Marg, Vikhroli (West), Mumbai – 400083.
Historical Stock Returns for Archit Organosys
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.92% | +2.49% | +2.09% | +30.78% | +22.53% | +33.56% |
Given the sharp shift from raw material consumption to stock-in-trade purchases in FY26, is Archit Organosys transitioning toward a trading-heavy business model, and how might this affect margins in FY27?
With operating cash flow declining significantly from ₹1,852 lakh in FY25 to ₹268 lakh in FY26 despite higher net profits, what working capital pressures could emerge in the coming year?
As Q4 FY26 revenue dropped notably compared to Q4 FY25, does this signal a potential demand slowdown in the chemicals and organics segment that could weigh on FY27 top-line growth?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
